bioRxivImmunology
Plant-produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variants
T. Mammedov, D. Yuksel, I. Grbzaslan, M. Ilgn, B. Gulec, G. Mammadova, A. Ozdarendeli, S. T. Islam Pavel, H. Yetiskin, B. Kaplan, M. A. Uygut, G. Hasanova
Abstract
SARS-CoV-2 is a novel and highly pathogenic coronavirus, which has caused an outbreak in Wuhan City, China, in 2019 and then spread rapidly throughout the world. Although several COVID-19 vaccines are currently available for mass immunization, they are less effective against emerging SARS-CoV-2 variants, especially the Omicron (B.1.1.529). Recently, we successfully produced receptor-binding domain (RBD) variants of spike (S) protein of SARC-CoV-2 and an antigen cocktail in Nicotiana benthamiana, which are highly produced in plants and elicited high-titer antibodies with potent neutralizing activity against SARS-CoV-2. In this study, we demonstrate that these protein-based vaccine candidates are highly effective against Delta and Omicron variants. These data support that plant produced RBD and cocktail-based antigens are most promising vaccine candidates and may protect against Delta and Omicron-mediated COVID-19. Based on the neutralization ability, plant produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variants.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Engineering, production and characterization of Spike and Nucleocapsid structural proteins of SARS-CoV-2 in Nicotiana benthamiana as vaccine candidates against COVID-19
T. Mammedov, D. Yuksel, … G. Hasanova·bioRxiv·Dec 29, 2020
- Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants
- Plant-based production of SARS-CoV-2 antigens for use in a subunit vaccine
J. J. Demone, M. Maltseva, … A. M. MacLean·bioRxiv·Oct 17, 2021
- Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine
D. Li, D. R. Martinez, … B. F. Haynes·Nature CommunicationsPeer-reviewed·Oct 23, 2022
- SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1
J. L. M. Law, M. Logan, … M. Houghton·bioRxiv·May 10, 2021
- Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants
K. A. Parham, G. N. Kim, … R. M. Troyer·bioRxiv·Jul 19, 2022